Maxim Grymonprez
15PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (15)
Sort by Publication Date:
|Sep 10, 2025
Predictors of mortality and hospitalised exacerbations in obstructive airway diseases.Delphine Vauterin, Frauke Van Vaerenbergh, Maxim Grymonprez
|Oct 14, 2024
Anticoagulant-related bleeding as a sign of underlying tumoural lesions in patients with atrial fibrillation: a nationwide cohort study.Kristiaan Proesmans, Maxim Grymonprez, Sylvie Rottey
|Nov 06, 2023
Pharmacodynamic Drug-Drug Interactions and Bleeding Outcomes in Patients with Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants: a Nationwide Cohort Study.Maxim Grymonprez, Andreas Capiau, Stephane Steurbaut
|Oct 04, 2023
Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study.Maxim Grymonprez, Laura Carnoy, Andreas Capiau
|Sep 14, 2023
Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death: A Nationwide Cohort Study.Maxim Grymonprez, Stephane Steurbaut, Andreas Capiau
|Jun 27, 2023
The Impact of Polypharmacy on the Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation.Maxim Grymonprez, Mirko Petrovic, Tine L De Backer
Pageof 3
